<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14983">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232583</url>
  </required_header>
  <id_info>
    <org_study_id>1003-623</org_study_id>
    <nct_id>NCT00232583</nct_id>
  </id_info>
  <brief_title>Preservation of Beta-cell Function in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Preservation of Beta-cell Function in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic
      patients on two different treatment regimens: insulin and metformin versus glyburide,
      metformin and pioglitazone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell
      function, as well as glycemic control and inflammatory markers in newly diagnosed type 2
      diabetic patients on two different treatment regimens: insulin and metformin versus
      glyburide, metformin and pioglitazone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Beta-cell Function</measure>
    <time_frame>Change from 0 to 72 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>C-peptide AUC during a 3-HR MMCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance (HOMA)</measure>
    <time_frame>72 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Control</measure>
    <time_frame>72 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Change</measure>
    <time_frame>72 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>72 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, Treatment Satisfaction, and Treatment Compliance</measure>
    <time_frame>72months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metfomin and Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin, Pioglitazone and Glyburide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000mg/BID</description>
    <arm_group_label>Metfomin and Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin Novolg 70/30 per protocol titration</description>
    <arm_group_label>Metfomin and Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metfomin</intervention_name>
    <description>Metformin 1000mg/BID</description>
    <arm_group_label>Metformin, Pioglitazone and Glyburide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 45mg</description>
    <arm_group_label>Metformin, Pioglitazone and Glyburide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glyburide</intervention_name>
    <description>Glyburide per protocol titration</description>
    <arm_group_label>Metformin, Pioglitazone and Glyburide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus diagnosed within the prior 2 months

          -  HbA1c &gt; 7% at the time of inclusion

          -  willing to perform intensive diabetes management

          -  able to comply with treatment and follow-up regimen

        Exclusion Criteria:

          -  HbA1c &gt; 8% at time of randomization

          -  creatinine &gt; 1.5 mg/dl

          -  liver function tests &gt; 3 times the upper limit of normal

          -  severe anemia

          -  severe proliferative retinopathy

          -  NYHA class III or IV heart failure

          -  active CAD or recent (within 6 months) MI

          -  pregnant, willing to get pregnant, or not willing to practice any contraceptive
             method

          -  non-english speaking

          -  active heavy alcohol or illicit drug users (within past 6 months)

          -  history of lactic acidosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Raskin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ildiko Lingvay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 2007 Mar;55(2):62-8.</citation>
    <PMID>17362692</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>May 26, 2015</lastchanged_date>
  <firstreceived_date>September 30, 2005</firstreceived_date>
  <firstreceived_results_date>October 15, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Ildiko Lingvay</investigator_full_name>
    <investigator_title>MD, MPH, MSCS</investigator_title>
  </responsible_party>
  <keyword>TYpe 2 diabetes mellitus</keyword>
  <keyword>Newly diagnosed</keyword>
  <keyword>Beta-cell function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glyburide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited at UT Southwestern Clinical Diabetes Research Office</recruitment_details>
      <pre_assignment_details>A 3-months run-in period preceeded randomization. During this period all patients were treated with insulin and metformin.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metfomin &amp; Insulin</title>
        </group>
        <group group_id="P2">
          <title>Metfomin, Pioglitazone &amp; Glyburide</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metfomin &amp; Insulin</title>
        </group>
        <group group_id="B2">
          <title>Metfomin, Pioglitazone &amp; Glyburide</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="44.8" spread="9.7"/>
                <measurement group_id="B2" value="45.0" spread="10.7"/>
                <measurement group_id="B3" value="44.9" spread="10.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="37"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Beta-cell Function</title>
        <description>C-peptide AUC during a 3-HR MMCT</description>
        <time_frame>Change from 0 to 72 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Metformin &amp; Insulin</title>
          </group>
          <group group_id="O2">
            <title>Metformin, GLyburide &amp; Pioglitazone</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Beta-cell Function</title>
            <description>C-peptide AUC during a 3-HR MMCT</description>
            <units>ng*min/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2096" spread="795"/>
                  <measurement group_id="O2" value="1725" spread="618"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Resistance (HOMA)</title>
        <time_frame>72 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Control</title>
        <time_frame>72 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Change</title>
        <time_frame>72 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Markers</title>
        <time_frame>72 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life, Treatment Satisfaction, and Treatment Compliance</title>
        <time_frame>72months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metfomin &amp; Insulin</title>
        </group>
        <group group_id="E2">
          <title>Metfomin, Pioglitazone &amp; Glyburide</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI disturbance</sub_title>
                <description>Gastrointestinal disturbance including nausea, diarrhea, flatulence, vomiting.</description>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="18" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively small trial, but longest (6-year) follow-up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ildiko Lingvay</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-2779</phone>
      <email>ildiko.lingvay@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
